TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04238780

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl patient control device
Description: 24-hour fentanyl consumption will be recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl patient control device
Description: 24-hour fentanyl consumption will be recorded.
Study: NCT01410448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Steroids were administered according to local clinical practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Steroids were administered according to local clinical practice.
Study: NCT01185574

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Vitamin D2 50,000 IU will be administered once a week for six months.
Study: NCT02535065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith Low Profile AAA Endovascular Graft and ancillary components
Description: Treatment of patients with abdominal aortic, aortoiliac, or iliac aneurysms having morphology suitable for endovascular repair
Study: NCT03708939

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Daily consumption of 5g of glucose, for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspartame
Description: Daily consumption of six commercially available sachets containing aspartame and glucose as bulking agent (1g each sachet), for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Daily consumption of six commercially available sachets containing sucralose and glucose as bulking agent (1g each sachet), for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharin
Description: Daily consumption of six commercially available sachets containing saccharine and glucose as bulking agent (1g each sachet), for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stevia
Description: Daily consumption of six commercially available sachets containing Stevia and glucose as bulking agent (1g each sachet), for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Supplement
Description: Follow up without any dietary supplementation.
Study: NCT02045758

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fingerstick

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAP20-C
Study: NCT03126851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label
Description: Labels vary based on presence or absence of age range information, and inclusion of an explicit warning in words, with or without a pictographic icon.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label
Description: Labels vary based on presence or absence of age range information, and inclusion of an explicit warning in words, with or without a pictographic icon.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label
Description: Labels vary based on presence or absence of age range information, and inclusion of an explicit warning in words, with or without a pictographic icon.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label
Description: Labels vary based on presence or absence of age range information, and inclusion of an explicit warning in words, with or without a pictographic icon.
Study: NCT01946087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning at left upper arm
Description: Placement of automated cuff-inflator on the left upper arm after induction of anesthesia RIPCgroup-3 cycles of 5 min ischemia (300 mmHg inflation) \& 5 min reperfusion (deflation)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: keeping the cuff deflated
Study: NCT01672307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil lotion 2%
Description: Minoxidil lotion 2% is applied twice daily to one eyebrow.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is applied twice daily to the other eyebrow.
Study: NCT01887860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil Daily Facial Moisturizer SPF 50
Description: Other: Cetaphil Daily Advance Ultra Hydrating Lotion 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
Study: NCT00897429

Intervention type: PROCEDURE
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01412073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: misoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby \& the placenta
Study: NCT00709020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: white button mushroom extract
Description: Dose escalation with six evaluable subjects per dose level. Doses begin at 5 g/day, then 8 g/day, then 10 g/day then 13 g/day.
Study: NCT01836471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 supplied as hard gelatin capsule in unit dose strength of 150 mg. Patient took 450 mg once daily (3 capsules taken with food in the morning) for the approximate period of the study (12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 supplied as hard gelatin capsule in unit dose strength of 150 mg. Patient took 450 mg once daily (3 capsules taken with food in the morning) for the approximate period of the study (12 weeks)
Study: NCT00709020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Performed on blood samples taken pre-treatment on day 1 and on day 85 after treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Performed on blood samples taken on days 1, 8, 15, 29, 57 and 85 of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Performed on blood samples taken pre-dose and at 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours after White Button Mushroon extract on day 1 of treatment and pre-dose on days 8, 15, 29, 57 and 85 after start of treatment.
Study: NCT03797365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical rehabilitation
Description: Participants will benefit from two-phases perineal rehabilitation:~First phase will include the PFM's awareness and voluntary contraction learning with manual, biofeedback technics and functional electro stimulation. These exercises will call out the manual rehabilitation technics, biofeedback and electro stimulation. Each classical rehabilitation session will take 30 minutes with 20 minutes of active working, twice per week. About the self-training, there will be no consensus for optimal homemade exercises.~For the second phase, a behavior analyze will be summarized in order to update the favoring and inappropriate situations. The strategy put in place will be organized in unlearning of deleterious perineal habits and learning new behavior program. The main goal will be the perineal locking set up, which must be systematic before and during efforts. During this phase, the physiotherapist will twice weekly perform evaluations (similar to those in the first phase)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive associated rehabilitation
Description: The cognitive associated rehabilitation group randomized participants will have to execute twice a day the rehabilitation protocol. Each cognitive rehabilitation session will take three minutes. Participants will have to synergistically execute attentional tests (N-Back Test) and execute a perineal contraction during the contraction instructions. (10 randomized auditory stimuli in three minutes). The attentional tests' difficulty will be gradually increased each 15 days. N-Back Test modalities are the followings: the participant will visualize a series of random numbers. First difficulty step will be to click the dedicated button when the volunteer will see the indicated letter. The second difficulty step will be to click the dedicated button when she will see two consecutives times the same letter. The third difficulty step will be to click the dedicated button when she will see two times the same letter separated by one different letter, and so on...
Study: NCT01836471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo QAW039
Description: Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
Study: NCT02493088

Intervention type: OTHER
Intervention: Antisocial personality recording of behavior and contextual elements
Description: aberrant driving behaviors and upstream contextual elements of individuals diagnosed with antisocial personality disorder will be recorded during the study
Study: NCT01233193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education, Home blood pressure monitoring
Description: Health education (on hypertension, smoking, healthy diet, obesity, physical inactivity and adherence to antihypertensive medications and home blood pressure monitoring) . The patient will be referred to physician when needed. The patient will be followed up during 6 months.
Study: NCT01836471

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo QAW039
Description: Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo QAW039
Description: Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
Study: NCT00475111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Pain (CBT-P)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation for Emotion Regulation (MM-ER)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis education
Study: NCT01836471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 250 mcg
Description: Fluticasone was supplied in inhalers with dose strength of 250 mcg. Patients took 250 mcg bid (morning and evening approximately 12 hours between doses) for a total dose of 500 mcg daily for the approximate period of the study (12 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone 100 mcg
Description: Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone 100 mcg
Description: Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone 100 mcg
Description: Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone 100 mcg
Description: Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).
Study: NCT01955928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive behavioral treatment for insomnia
Study: NCT01169844

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457A
Study: NCT04692311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: an intelligent client-centred task-oriented training
Description: 3 x 45min of training with i-ACT system

Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interview
Description: Participants, patients and therapists, were invited to a semi-structured interview after training period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-structured interview
Description: Participants, patients and therapists, were invited to a semi-structured interview after training period.
Study: NCT03535792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl/Hyperbaric bupivacaine
Description: Intrathecal Fentanyl/Hyperbaric bupivacaine and Tibial internal fixation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine/Hyperbaric bupivacaine
Description: Intrathecal Nalbuphine/Hyperbaric bupivacaine and Tibial internal fixation.
Study: NCT02429063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright White Light
Description: The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The BWL Litebook® looks identical to the DRL and utilizes 24 white light-emitting diode (LED) lights and does not emit ultraviolet light.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dim Red Light
Description: The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The DRL Litebook looks identical to the BWL box and contains red lights rather than white LED lights.
Study: NCT04198662

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoneurolysis with a Painblocker (Epimed International, Farmers Branch, Texas)
Description: The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intercostal nerve block ropivacaine with epinephrine
Description: 3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block(s)
Study: NCT02015611

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2,000 IU/ day of Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04733066

Intervention type: DRUG
Intervention: Teduglutide
Description: Intervention group consists of patients, who receive teduglutide within routine medical care
Study: NCT02478762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal glycemic control
Description: Use diet, physical exercise of insulins to reach normal glycemic control.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low glycemic control
Description: Use diet, physical exercise of insulins to reach low glycemic control.
Study: NCT00004208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG + CSA
Description: Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Supportive care
Description: Patients randomized to this arm will be treated as outpatients.
Study: NCT01207024

Intervention type: OTHER
Intervention: knee MRI
Description: knee MRI before surgery (inclusion) and one year after
Study: NCT00766012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16. Specific dose depends on dose panel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16.
Study: NCT03126968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical epinephrine
Description: Prophylactic topical epinephrine
Study: NCT00376259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine
Description: 600mg/day oral tablet for 96 weeks
Study: NCT03126968

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Topical placebo (normal saline)
Study: NCT02724319

Intervention type: DEVICE
Intervention: SpartanRX
Description: A buccal swap genetic sample will be collected from eligible patients who provide written informed consent for CYP2C19 testing. Genotyping will be performed by the SpartanRX system as a clinical test at the UF Health Pathology Laboratory in Jacksonville.
Study: NCT04432766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2020
Description: After a cohort completes the study on Day 28, data on safety and tolerability for each cohort will be evaluated by the Safety Monitoring Committee (SMC). Administration of the next higher dose to a new dosing cohort will be permitted only if adequate safety and tolerability have been demonstrated. If encouraging clinical benefit is observed at a certain dose level, the study may proceed to a to Part 2 based on emerging data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2020
Description: After a cohort completes the study on Day 28, data on safety and tolerability for each cohort will be evaluated by the Safety Monitoring Committee (SMC). Administration of the next higher dose to a new dosing cohort will be permitted only if adequate safety and tolerability have been demonstrated. If encouraging clinical benefit is observed at a certain dose level, the study may proceed to a to Part 2 based on emerging data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2020
Description: After a cohort completes the study on Day 28, data on safety and tolerability for each cohort will be evaluated by the Safety Monitoring Committee (SMC). Administration of the next higher dose to a new dosing cohort will be permitted only if adequate safety and tolerability have been demonstrated. If encouraging clinical benefit is observed at a certain dose level, the study may proceed to a to Part 2 based on emerging data.
Study: NCT01692860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: Subjects consume 750 kcal/d of energy below their need

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Energy Restriction
Description: Subjects consume 750 kcal/d of energy below their need
Study: NCT03660930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus Albumin-bound Nanoparticles
Description: Given IV
Study: NCT04198662

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cryoneurolysis with a Painblocker
Description: The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo intercostal nerve block with normal saline
Description: 3 mL of normal saline will be injected perineurally to provide placebo intercostal nerve blocks
Study: NCT02555046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Use of unspecified local anaesthesia (fx lidocain or bupivacaine)
Study: NCT02009475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continues aerobic training
Study: NCT01169844

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIN457A